We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more

Link to third party site

The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

364 Search Results

Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.

Ogiwara K, Taki M, Suzuki T, et al. BMJ Open. 2022 Feb 17;12(2):e056922

Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.

Nakajima Y, Mizumachi K, Shimonishi N, et al. Int J Hematol. 2022 Apr;115(4):489-498

Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma.

Takeyama M, Furukawa S, Onishi T, et al. Pediatr Blood Cancer. 2022 Apr 20:e29731

AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors.

Matsushita T, Suzuki N, Nagao A, et al. BMJ Open. 2022 Mar 14;12(3):e057018

Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting.

Gourzoulidis G, Stefanou G, Economou M, et al. Clin Drug Investig. 2022 Jan;42(1):75-85

Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru.

Bitrán R, Peña C, Arpón P, et al. Medwave. 2022 Mar 15;22(2):e8703

Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen.

Bukkems LH, Fischer K, Kremer-Hovinga I, et al. Thromb Haemost. 2022 Feb;122(2):208-215